[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582346":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":46,"collaborators":24,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":24,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":24,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":24,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Kasr El Aini Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"stop RAS","EXPERIMENTAL","When the ACE-I and\u002For ARB duration of action is ≥24 hours, the drug will be stopped 48 hours prior to surgery. All other ACE-I and\u002For ARB will be stopped 24 hours before surgery.",[13],"Drug: ACE-I and\u002For ARB antihypertensive treatment",{"label":15,"type":16,"description":17,"interventionNames":18},"continue RAS","ACTIVE_COMPARATOR","ACE-I and ARBs will be continued till morning of surgery",[13],[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","ACE-I and\u002For ARB antihypertensive treatment",[15,9],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Khaled Sarhan, MD","CONTACT","+201020067816","khaled.sarhan@kasralainy.edu.eg",[32],{"facility":33,"status":34,"city":35,"state":24,"zip":24,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Cairo university hospitals","RECRUITING","Cairo","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],31.24967,30.06263,{"lat":42,"lon":41},[45],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Khaled Abdelfattah Abdallah Sarhan","principal investigator, Asst. professor of anesthesia, Cairo university","100582346","phase-3-the-effect-of-discontinuation-of-renin-angiotensin-system-inhibitors-on-the-perioperative-myocardial-injury-in-adult-patients-undergoing-colorectal-cancer-surgery-100582346",false,"NCT06862115","The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery","The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery: a Randomized Controlled Non Inferiority Study.","Inclusion Criteria:\n\n* Age \\> 18 years\n* Both sexes\n* ASA 2-3\n* Chronic hypertensive patients (\\> 3 months before surgery) controlled on ACEIs or ARBs or combination therapy containing one of the RAS inhibitors.\n* Scheduled for major abdominal cancer surgery (surgery with an expected duration of \\> 2 h from the surgical incision and a postoperative hospital stay of least three days).\n\nExclusion Criteria:\n\n* Patient refusal.\n* Recent myocardial infarction (within 3 months).\n* Any condition, which in the opinion of the treating clinician, would result in the patient being harmed by the cessation of the ACE-I and\u002For ARB therapy.\n* Emergency surgery","ALL","18 Years","70 Years",{"count":61,"type":62},156,"ESTIMATED","INTERVENTIONAL",[65],"PHASE3","The aim of this study is to estimate the effect of discontinuation of RAS inhibitors on myocardial injury in cancer patients undergoing major abdominal surgeries.",[68,69,70],"Myocardium; Injury","Perioperative\u002FPostoperative Complications","Angiotensin-Converting-Enzyme Inhibitor","2025-11-16",{"date":73,"type":74},"2025-11-18","ACTUAL",{"date":76,"type":74},"2025-03-01",{"date":78,"type":62},"2026-01-01",{"name":5,"class":6},1]